Skip to main content
Torrent Pharmaceuticals Ltd. logo

Torrent Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · TORNTPHARM ISIN · INE685A01028 LEI · 335800NA6HK275RIJE13 BSE.NS Manufacturing
Open in API
Filings indexed 1,756 across all filing types
Latest filing 2025-09-24 Capital/Financing Update
Country IN India
Listing BSE.NS TORNTPHARM

About Torrent Pharmaceuticals Ltd.

https://www.torrentpharma.com

Torrent Pharmaceuticals Ltd. is a research-driven organization focused on the development, manufacturing, and marketing of generic formulations. The company holds a significant position in therapeutic areas such as cardiovascular, central nervous system, gastrointestinal, diabetology, and anti-infective treatments. It has strategically expanded its portfolio into dermatology, nephrology, and pain management through targeted acquisitions. The firm operates across multiple international markets, supported by advanced research and development centers and manufacturing facilities that adhere to global regulatory standards. Its core operations prioritize chronic therapy leadership and the provision of high-quality healthcare solutions through a robust pipeline of generic and value-added medicines.

Recent filings

Filing Released Lang Actions
Issue of Securities
Capital/Financing Update Classification · 100% confidence The document is a formal letter addressed to the stock exchanges (BSE and NSE) regarding the issuance of Commercial Papers by the company. It provides details such as issue size, tenure, interest rate, and listing information. The document references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is an update on a financing activity (issuance of commercial papers) rather than a financial report, audit, or management discussion. The document length is short (2745 characters) and is clearly an announcement of a capital market transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-09-24 English
Intimation regarding issue of Commercial paper
Capital/Financing Update Classification · 100% confidence The document is a formal letter addressed to the stock exchanges (BSE and NSE) regarding the issuance of Commercial Papers by the company. It provides details such as issue size, tenure, interest rate, and listing information. The document references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is an announcement about a financing activity (issue of commercial papers) rather than a financial report or audit. The document length is short (2745 characters) and it is clearly an update on capital raising. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-09-24 English
Disclosure under Regulation 30 and other applicable provisions of SEBI LODR Regulations, 2015
M&A Activity Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges (BSE and NSE) regarding regulatory approval from the Competition Commission of South Africa for an acquisition transaction. It references previous media releases and stock exchange intimations about the acquisition of a controlling stake in J. B. Chemicals & Pharmaceuticals. The document is brief (1489 characters) and serves as an update on a regulatory approval related to a merger/acquisition transaction. It does not contain financial statements or detailed financial data, nor is it a full report or presentation. Therefore, it fits best under the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2025-09-23 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to the stock exchange listing department, disclosing an update under SEBI Listing Regulations about the approval from the Competition Commission of South Africa for a previously announced acquisition transaction. It references prior media releases and stock exchange intimations but does not contain detailed financial data or a full report. The document length is only 1489 characters, indicating it is a brief announcement rather than a full report. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement updating on a transaction approval without detailed financials or report content.
2025-09-23 English
Redemption of Commercial papers issued under ISIN: INE685A14146
Capital/Financing Update Classification · 95% confidence The document is a short official communication from Torrent Pharmaceuticals Limited informing the stock exchanges (BSE and NSE) about the full redemption and repayment of Commercial Papers (CPs) amounting to ₹200 crores on the maturity date. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events. The content is a straightforward update on a financing activity (redemption of debt instruments) without detailed financial statements or analysis. The document length is only 1212 characters, indicating it is a brief announcement rather than a detailed report. Therefore, this fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2025-09-18 English
Updates
Capital/Financing Update Classification · 100% confidence The document is a short official letter dated 18th September 2025 from Torrent Pharmaceuticals Limited addressed to stock exchanges (BSE and NSE). It informs about the full redemption and repayment of Commercial Papers (CPs) of ₹200 crores on the maturity date. The letter references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events. The content is an update on a financing activity (redemption of debt instruments). The document length is only 1212 characters, indicating it is a brief announcement rather than a detailed report. Therefore, this fits the category of Capital/Financing Update (CAP) rather than a full financial report or regulatory filing.
2025-09-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.